Pure Global AI
NCT06311578Recruiting

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
JNJ-87704916
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Johnson & Johnson Enterprise Innovation Inc.
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Apr 10, 2024
End date
Nov 30, 2033
Enrollment
66 participants
Primary outcome

Part 1: Number of Participants with Dose-Limiting Toxicity (DLT),Number of Participants with Adverse Events (AEs) by Severity

Summary

The purpose of this study is to determine the safety, feasibility, recommended dose(s) and
 regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06311578
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06311578 through Pure Global AI's free database. This Phase 1 trial is sponsored by Johnson & Johnson Enterprise Innovation Inc. and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 66 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.